A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Priovant Therapeutics, Inc.
Study ID
NCT07532603
Phase
PHASE2/PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Lichen Planopilaris

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Oral Brepocitinib — DRUG
    Oral
  • Placebo — DRUG
    Oral

Study Details

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris

Key Dates

Start date
Mar 19, 2026
Status verified
Apr 2026
Primary completion
Dec 31, 2028
Completion
Jul 31, 2029

Study Design

Enrollment
342 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Brepocitinib Dose Level 1
  • Placebo Comparator: Placebo

Primary Outcome Measure

Proportion of participants achieving IGA score 0/1 and ≥ 2-step reduction from baseline at Week 24 [ Time Frame: Week 24 ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
Clinical Trial SitePhoenixArizona85006-
Clinical Trial SitePortlandOregon97210-
Clinical Trial SiteSmyrnaTennessee37167-
Clinical Trial SiteAustinTexas78613-
Clinical Trial SiteCedar ParkTexas78613-

Find similar trials in Phoenix, AZ

By research site
Clinical Trial Site· Phoenix, AZClinical Trial Site· Portland, ORClinical Trial Site· Smyrna, TNClinical Trial Site· Austin, TXClinical Trial Site· Cedar Park, TX

Related Studies